Kasparová P, Smolej L
Fingerlandův ustav patologie, Fakultní nemocnice, Univerzity Karlovy, Hradec Králové.
Cesk Patol. 2007 Apr;43(2):50-8.
Angiogenesis is a process of formation of new vessels from the preexisting ones. It is involved in many physiological processes, at the same time, however, it is involved also in the progress of tumoral growth. Although a lot is known about angiogenesis in solid tumors where it plays a role in tumoral invasion and its metastatic potential, in hematological malignancies it has been appreciated only recently. However, the results of studies on abnormal angiogenesis in hematological malignancies are inconsistent. Angiogenesis can be studied at different levels; histologically, it is studied in the infiltrated tissues (lymph nodes, bone marrow) and quantified as microvessel density (MVD). The aims of our study were to introduce the method of MVD quantification in the bonemarrow using immunohistochemical detection of endothelial markers (fVIII) and then evaluate MVD in bone marrow samples in a group of patients with chronic lymphocytic leukaemia (CLL) and compare the results with a control group of patients (CON). CLL is a typical malignancy of the hematopoietic tissue but the course and the prognosis of patients with this disease vary considerably. For this reason there is urgent need for novel prognostic markers in order to assess individual patient prognosis and tailor treatment. Angiogenesis is one of the possible markers which may add more informations about the course of this disease. So far only few studies have been published about angiogenesis measured as MVD in CLL patients andthe results are inconsistent. In our study, both the number and the area of microvessels were increased in bone marrow of patients with CLL, but the number and area of sinuses were not. It can be concluded that there are signs of abnormal angiogenesis in bone marrow of patients with CLL but larger study with longer follow-up is needed to give more specific information about prognostic value of these findings.
血管生成是一个从已有的血管形成新血管的过程。它参与许多生理过程,然而,与此同时,它也参与肿瘤生长的进程。尽管在实体瘤中血管生成在肿瘤侵袭及其转移潜能方面发挥作用,人们对此已经了解很多,但在血液系统恶性肿瘤中,直到最近它才受到关注。然而,关于血液系统恶性肿瘤中异常血管生成的研究结果并不一致。血管生成可以在不同层面进行研究;从组织学角度,在浸润组织(淋巴结、骨髓)中进行研究,并将微血管密度(MVD)作为量化指标。我们研究的目的是引入使用内皮标志物(因子VIII)免疫组化检测来量化骨髓中MVD的方法,然后评估一组慢性淋巴细胞白血病(CLL)患者骨髓样本中的MVD,并将结果与对照组患者(CON)进行比较。CLL是造血组织的一种典型恶性肿瘤,但这种疾病患者的病程和预后差异很大。因此,迫切需要新的预后标志物来评估个体患者的预后并制定个性化治疗方案。血管生成是可能的标志物之一,它可能为这种疾病的病程提供更多信息。到目前为止,关于以MVD衡量的CLL患者血管生成的研究仅有少数发表,且结果并不一致。在我们的研究中,CLL患者骨髓中的微血管数量和面积均增加,但血窦的数量和面积未增加。可以得出结论,CLL患者骨髓中存在异常血管生成的迹象,但需要进行更大规模、更长随访时间的研究,以提供关于这些发现预后价值的更具体信息。